Obermatt
See Similar Stocks →

Voyager Therapeutics

NSQ:VYGR · US92915B1061
BiotechnologySmall

360

49
Profit price30
Owner Earnings Yield1
Dividend Yield1
Price/Sales80
Price/Book46
Return on Capital59
Cash Return on Capital58
Return on Equity63
Profit margins21
Accruals74
Owner Earnings Margin55
Sales growth67
Profit growth51
Reinvestment16
Price momentum26
Debt load40
Refinancing43
Debt Payback1
Liquidity64
Analyst ratings100
Expectations trend50
Market mood61
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Voyager Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees147
Websitevoyagertherapeutics.com
ISINUS92915B1061
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyGeneticsNeuroscienceOncologyCentral Nervous SystemGenetic DisorderBiotechnologyHealth CareLife Science

Description

Voyager Therapeutics, Inc. operates as a biotechnology company. The company is leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. The company's pipeline includes programs for Alzheimer's disease…

Analysis

Middle-of-the-road

Voyager Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
57
2026

All-time high

57

Jun 2026

All-time low

56

Mar 2026

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
—
—
—
Price/Earnings
18
—
—
—
Price/Book
46
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
30
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Voyager Therapeutics with its peers
MeiraGTx
NSQ:MGTX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Taysha Gene Therapies
NSQ:TSHA
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Beam Therapeutics
NSQ:BEAM
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Regenxbio
NSQ:RGNX
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →